Osteoarthritis patients now have a safer, more efficient, and minimally invasive treatment thanks to a recent breakthrough in stem cell-derived options.

Hong Kong Science and Technology Parks Corporation (HKSTP) partner companies,Hong Kong Regen MedTech Limited (HKRM) and Cordlife Hong Kong Limited (Cordlife), recently revealed a joint project involving Mesenchymal Stem Cells (MSCs) biology, which is expected to accelerate the progress of regenerative medicine for patients with degenerative arthritis.

Osteoarthritis is a debilitating condition that can cause immense suffering, with 35,000 Hong Kongers currently on a waiting list for joint replacement surgery. Whilst non-surgical management through hyaluronic acid or corticosteroid injections is effective for some, these medications may not be suitable for all patients, and there are concerns about their side effects. Furthermore, artificial joints have a lifespan of approximately 20 years, so the suitability of this form of treatment must be judged carefully by a doctor.

At Hong Kong Science Park, HKRM and Cordlife, partners of HKSTP’s “Medtech Co-Create” programme, held a press conference titled “Advancing Stem Cell Therapy: A Journey of Collaboration and Innovation”. The goal of this collaboration between the two companies was to increase public awareness of regenerative medicine, and to further its development in Hong Kong, offering patients with osteoarthritis a safe, effective, and minimally invasive treatment. With the rapid growth of this technology, there are promising prospects on the horizon.